Literature DB >> 6601196

Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product.

R B Naso, L H Stanker, J J Kopchick, V L Ng, W L Karshin, R B Arlinghaus.   

Abstract

A glycosylated 45,000-Mr protein containing Rauscher murine leukemia virus p15 and p12 antigenic sites and tryptic peptides was identified in Rauscher murine leukemia virus-infected cells. This glycoprotein, termed gP45gag, was also shown to contain a single tryptic peptide also present in gPr80gag and its unglycosylated apoprotein precursor Pr75gag, but lacking in Pr65gag or Pr40gag. The presence of this peptide only in viral precursor proteins containing the so-called leader (L) sequence strongly suggests that gPr45gag is an N-terminal fragment of larger glycosylated gag polyproteins, composed of L sequences in addition to p15 and p12. The kinetics of appearance of radiolabeled gPr45gag and its disappearance during chase-incubation is suggestive of a precursor-like role for this intermediate gene product. An observed 27,000-Mr glycosylated polypeptide, termed gP27gag and containing p15 but not p12, p30, or p10 antigenic determinants, is a candidate cleavage product derived from gPr45gag. These observations suggest that gPr45gag and its putative cleavage product gP27gag represent an authentic pathway for intracellular processing of glycosylated core proteins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601196      PMCID: PMC256534     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Selective decrease in the rate of cleavage of an intracellular precursor to Rauscher leukemia virus p30 by treatment of infected cells with actinomycin D.

Authors:  G A Jamjoom; R B Naso; R B Arlinghaus
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

2.  Biosynthesis of Rauscher leukemia viral proteins: presence of p30 and envelope p15 sequences in precursor polypeptides.

Authors:  L J Arcement; W L Karshin; R B Naso; G Jamjoom; R B Arlinghaus
Journal:  Virology       Date:  1976-02       Impact factor: 3.616

3.  Common precursor for Rauscher leukemia virus gp69/71, p15(E), and p12(E).

Authors:  W L Karshin; L J Arcement; R B Naso; R B Arlinghaus
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

4.  Biosynthesis of Rauscher leukemia viral proteins.

Authors:  R B Naso; L J Arcement; R B Arlinghaus
Journal:  Cell       Date:  1975-01       Impact factor: 41.582

5.  Further characterization of intracellular precursor polyproteins of Rauscher leukemia virus.

Authors:  G A Jamjoom; R B Naso; R B Arlinghaus
Journal:  Virology       Date:  1977-05-01       Impact factor: 3.616

6.  "gag" polyprotein precursors of Rauscher murine leukemia virus.

Authors:  L J Arcement; W L Karshin; R B Naso; R B Arlinghaus
Journal:  Virology       Date:  1977-09       Impact factor: 3.616

7.  Biosynthesis of reverse transcriptase from Rauscher murine leukemia virus by synthesis and cleavage of a gag-pol read-through viral precursor polyprotein.

Authors:  J J Kopchick; G A Jamjoom; K F Watson; R B Arlinghaus
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

8.  Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus.

Authors:  L H Evans; S Dresler; D Kabat
Journal:  J Virol       Date:  1977-12       Impact factor: 5.103

9.  Purification of large amounts of murine ribonucleic acid tumor viruses produced in roller bottle cultures.

Authors:  J J Syrewicz; R B Naso; C S Wang; R B Arlinghaus
Journal:  Appl Microbiol       Date:  1972-09

10.  A core polyprotein of murine leukemia virus on the surface of mouse leukemia cells.

Authors:  J S Tung; T Yoshiki; E Fleissner
Journal:  Cell       Date:  1976-12       Impact factor: 41.582

View more
  4 in total

1.  Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane.

Authors:  E A Pillemer; D A Kooistra; O N Witte; I L Weissman
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

2.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.

Authors:  Angelo Kolokithas; Kyle Rosenke; Frank Malik; Duncan Hendrick; Lukas Swanson; Mario L Santiago; John L Portis; Kim J Hasenkrug; Leonard H Evans
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

4.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.